What is Stemgent?
Stemgent is dedicated to advancing stem cell research by collaborating with leading scientists to develop cutting-edge technology and application solutions. The company's mission centers on simplifying and supporting cellular reprogramming research through products designed by global stem cell researchers. Stemgent's offerings are accessible to a worldwide customer base, aiming to accelerate discoveries in the field of regenerative medicine and cellular biology.
How much funding has Stemgent raised?
Stemgent has raised a total of $40.8M across 5 funding rounds:
Series A
$6.5M
Series B
$14M
Other Financing Round
$2.7M
Private Equity
$6.3M
Private Equity
$11.3M
Series A (2008): $6.5M with participation from Morgenthaler Private Equity and HealthCare Ventures
Series B (2009): $14M led by Frazier Healthcare Partners and Morgenthaler Private Equity
Other Financing Round (2009): $2.7M supported by HealthCare Ventures and Morgenthaler Private Equity
Private Equity (2012): $6.3M featuring HealthCare Ventures LLC
Private Equity (2012): $11.3M backed by HealthCare Ventures LLC
Key Investors in Stemgent
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent venture capital firm with a focus on the life sciences sector, likely providing strategic capital and operational expertise to companies like Stemgent.
Morgenthaler Private Equity
Morgenthaler Private Equity is a seasoned investment firm specializing in technology and life sciences, bringing extensive experience in scaling companies and fostering innovation.
HealthCare Ventures LLC
HealthCare Ventures LLC is a dedicated venture capital firm concentrating on early-stage life science companies, indicating a strategic interest in Stemgent's foundational research and development.
What's next for Stemgent?
The substantial enterprise-level backing and recent strategic investment suggest Stemgent is poised for significant expansion and further technological development. This capital infusion will likely fuel advancements in their product pipeline, enhance research collaborations, and potentially broaden their market reach. The company's focus on supporting cellular reprogramming research positions it to capitalize on the growing demand for innovative tools in the biotechnology and pharmaceutical industries, driving future growth and scientific breakthroughs.
See full Stemgent company page
